Quick BMN-111 update

BioMarin lauched on 30th April 2015 the latest investors report.

An article from Benzinga.com said: "In the report, Cowen and Company noted, "BMN-111's Phase II proof-of-concept study in achondroplasia is on track to produce data from first three dosing cohorts in June. BioMarin is optimistic that '111 can induce a 50% increase in growth velocity, and/or improve trunk and extremities proportionality.  As achondroplasia could be a $2 billion dollars plus opportunity, we think good data would be a catalyst for shares".

Lets wait for the phase II partial report in June.